Navitoclax

Drug Profile

Navitoclax

Alternative Names: ABT-263; RG 7423; RG 7433

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; Genentech
  • Class Antineoplastics; Benzamides; Morpholines; Piperazines; Small molecules; Sulfones
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Lymphoid leukaemia; Lymphoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 17 Jul 2017 AbbVie plans a phase II trial for Myelofibrosis (Combination therapy, In adults, In the elderly, Second-line therapy or greater) (PO) (NCT03222609)
  • 05 Jun 2017 AbbVie plans a phase I trial for Acute lymphoblastic leukaemia (In children, In adults, Combination therapy, Second-line therapy or greater) (PO) (NCT03181126)
  • 14 Feb 2017 Rutgers terminates a phase II trial in Prostate cancer (Metastatic disease, Combination therapy, Hormone-refractory) in USA because the investigator left the organisation (NCT01828476)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top